Juno Bio Opens CLIA-Certified Sequencing Lab Dedicated to Women’s Health

Juno Bio, a women’s health company dedicated to closing the gender gap with precision vaginal microbiome testing and multi-omics analysis, has opened its first sequencing lab dedicated entirely to women’s health. The new facility in Oakland, California, comes after the company raised $3.8 million in funding from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.

Juno Bio’s platform offers a detailed, clinically actionable view of vaginal health, giving patients and practitioners insights into conditions that are often misunderstood or misdiagnosed.

The company has built one of the largest repositories on vaginal microbiome data, and has provided thousands of women with more precise testing and treatment protocols. Since launching its first wellness test, the company has sold over 20,000 tests organically, eventually evolving into a clinical platform; expanding its scientific and clinical infrastructure through pharmaceutical R&D partnerships; creating its own clinical lab, telehealth, and pharmacy integrations; and growing a network of medical advisors, including Anna Powell, MD, of Johns Hopkins, a specialist in reproductive infectious disease and vulvovaginal disorders.

“Vaginal microbiome testing has the potential to significantly reshape how we understand and manage vaginal health, particularly for patients with recurrent or unexplained symptoms,” said Powell. “While the field is still evolving, advances in sequencing and data interpretation are moving us closer to a future where more personalized, microbiome-informed care can complement existing diagnostic approaches.”

The company’s microbiome and STI test is designed to address gaps in women’s healthcare, where recurrent infections, fertility concerns, and menopause-related symptoms are misunderstood or inadequately treated. The test, processed in Juno’s CLIA-certified lab, analyzes 10,000 bacteria and fungi, along with four common STIs.

“Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women’s health,” said Hana Janebdar, founder and CEO. “We’ve built one of the largest repositories of vaginal microbiome data and deepened our partnerships across research and care delivery. This next chapter is about scaling that work, expanding access to more actionable care, and continuing to close the gender health gap. We’re incredibly grateful to our investors and partners for their trust in our team and our vision as we move into this next stage of growth.”  

Unlike traditional pathogen tests, Juno Bio can identify microbes associated with co-infections, subclinical conditions, and broader microbiome patterns that may influence care. The test can clarify potential drivers of bacterial vaginosis, yeast infections, aerobic vaginitis, cytolytic vaginosis, and estrogen-related changes.

“Juno Bio is setting a new standard for how vaginal health is understood and managed,” said Check Warner, co-founding partner at Ada Ventures. “What they’ve built at this stage, with this level of capital efficiency, is exceptional. We’re proud to support the team as they scale their clinical infrastructure and continue leading innovation in this critically underserved category.”

According to consumer data from Juno Bio, prior to using its test, 67.5% of customers had been incorrectly diagnosed (misdiagnosed, underdiagnosed, or overdiagnosed) and only 13% had been successfully treated. About half of users had co-infections, which are often missed by conventional testing but can significantly impact treatment outcomes.

“The vaginal microbiome is still one of the least understood systems in the body at a clinical scale. With our lab, we’re starting to build a measurement standard that clinicians can actually use,” said Leighton Turner, PhD, founder and CSO of Juno Bio. “We believe the level of detail from this kind of testing can meaningfully improve how vaginal healthcare is provided.”